BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fox GJ, Dobler CC, Marais BJ, Denholm JT. Preventive therapy for latent tuberculosis infection-the promise and the challenges. Int J Infect Dis 2017;56:68-76. [PMID: 27872018 DOI: 10.1016/j.ijid.2016.11.006] [Cited by in Crossref: 73] [Cited by in F6Publishing: 71] [Article Influence: 12.2] [Reference Citation Analysis]
Number Citing Articles
1 Jansen‐aaldring N, Berg S, Hof S. Patient support during treatment for active tuberculosis and for latent tuberculosis infection: Policies and practices in European low‐incidence countries. J Adv Nurs 2018;74:2755-65. [DOI: 10.1111/jan.13784] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Dooley KE, Savic R, Gupte A, Marzinke MA, Zhang N, Edward VA, Wolf L, Sebe M, Likoti M, Fyvie MJ, Shibambo I, Beattie T, Chaisson RE, Churchyard GJ. Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial. The Lancet HIV 2020;7:e401-9. [DOI: 10.1016/s2352-3018(20)30032-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
3 Graham J, Wong CE, Day J, McFaddin E, Ochsner U, Hoang T, Young CL, Ribble W, DeGroote MA, Jarvis T, Sun X. Discovery of benzothiazole amides as potent antimycobacterial agents. Bioorg Med Chem Lett 2018;28:3177-81. [PMID: 30172617 DOI: 10.1016/j.bmcl.2018.08.026] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
4 Norton S, Bag SK, Cho JG, Heron N, Assareh H, Pavaresh L, Corbett S, Marais BJ. Detailed characterisation of the tuberculosis epidemic in Western Sydney: a descriptive epidemiological study. ERJ Open Res 2019;5:00211-2018. [PMID: 31528636 DOI: 10.1183/23120541.00211-2018] [Reference Citation Analysis]
5 Sharma N, Basu S, Chopra KK. Achieving TB elimination in India: The role of latent TB management. Indian J Tuberc 2019;66:30-3. [PMID: 30797279 DOI: 10.1016/j.ijtb.2018.10.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
6 Huang CC, Becerra MC, Calderon R, Contreras C, Galea J, Grandjean L, Lecca L, Yataco R, Zhang Z, Murray M. Isoniazid Preventive Therapy in Contacts of Multidrug-Resistant Tuberculosis. Am J Respir Crit Care Med 2020;202:1159-68. [PMID: 32551948 DOI: 10.1164/rccm.201908-1576OC] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Verma M, Vishwanath K, Eweje F, Roxhed N, Grant T, Castaneda M, Steiger C, Mazdiyasni H, Bensel T, Minahan D, Soares V, Salama JAF, Lopes A, Hess K, Cleveland C, Fulop DJ, Hayward A, Collins J, Tamang SM, Hua T, Ikeanyi C, Zeidman G, Mule E, Boominathan S, Popova E, Miller JB, Bellinger AM, Collins D, Leibowitz D, Batra S, Ahuja S, Bajiya M, Batra S, Sarin R, Agarwal U, Khaparde SD, Gupta NK, Gupta D, Bhatnagar AK, Chopra KK, Sharma N, Khanna A, Chowdhury J, Stoner R, Slocum AH, Cima MJ, Furin J, Langer R, Traverso G. A gastric resident drug delivery system for prolonged gram-level dosing of tuberculosis treatment. Sci Transl Med 2019;11:eaau6267. [PMID: 30867322 DOI: 10.1126/scitranslmed.aau6267] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
8 Petersen E, Maeurer M, Marais B, Migliori GB, Mwaba P, Ntoumi F, Vilaplana C, Kim K, Schito M, Zumla A. World TB Day 2017: Advances, Challenges and Opportunities in the "End-TB" Era. Int J Infect Dis 2017;56:1-5. [PMID: 28232006 DOI: 10.1016/j.ijid.2017.02.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
9 Malik AA, Farooq S, Jaswal M, Khan H, Nasir K, Fareed U, Shahbaz S, Amanullah F, Safdar N, Khan AJ, Keshavjee S, Becerra MC, Hussain H. Safety and feasibility of 1 month of daily rifapentine plus isoniazid to prevent tuberculosis in children and adolescents: a prospective cohort study. Lancet Child Adolesc Health 2021;5:350-6. [PMID: 33770510 DOI: 10.1016/S2352-4642(21)00052-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
10 Tomov G, Voynov P, Bachurska S. Granulomatous Cheilitis or Tuberculid? Antibiotics 2022;11:522. [DOI: 10.3390/antibiotics11040522] [Reference Citation Analysis]
11 van de Water BJ, Meyer TN, Wilson M, Young C, Gaunt B, le Roux KW. TB prevention cascade at a district hospital in rural Eastern Cape, South Africa. Public Health Action 2021;11:97-100. [PMID: 34159070 DOI: 10.5588/pha.20.0055] [Reference Citation Analysis]
12 Lestari T, Graham S, van den Boogard C, Triasih R, Poespoprodjo JR, Ubra RR, Kenangalem E, Mahendradhata Y, Anstey NM, Bailie RS, Ralph AP. Bridging the knowledge-practice gap in tuberculosis contact management in a high-burden setting: a mixed-methods protocol for a multicenter health system strengthening study. Implement Sci 2019;14:31. [PMID: 30890160 DOI: 10.1186/s13012-019-0870-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
13 Knight GM, McQuaid CF, Dodd PJ, Houben RMGJ. Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modelling. Lancet Infect Dis 2019;19:903-12. [PMID: 31281059 DOI: 10.1016/S1473-3099(19)30307-X] [Cited by in Crossref: 48] [Cited by in F6Publishing: 23] [Article Influence: 16.0] [Reference Citation Analysis]
14 Steyn EC, Naidoo TM, Marais S, Heckmann JM. Tuberculosis in Myasthenia Gravis patients on immunosuppressive therapy in a high-risk area: Implications for preventative therapy. J Neurol Sci 2021;425:117447. [PMID: 33878657 DOI: 10.1016/j.jns.2021.117447] [Reference Citation Analysis]
15 Shrestha S, Kendall EA, Chang R, Joseph R, Kasaie P, Gillini L, Fojo AT, Campbell M, Arinaminpathy N, Dowdy DW. Achieving a "step change" in the tuberculosis epidemic through comprehensive community-wide intervention: a model-based analysis. BMC Med 2021;19:244. [PMID: 34645429 DOI: 10.1186/s12916-021-02110-5] [Reference Citation Analysis]
16 Eng WS, Rejman D, Pohl R, West NP, Woods K, Naesens LMJ, Keough DT, Guddat LW. Pyrrolidine nucleoside bisphosphonates as antituberculosis agents targeting hypoxanthine-guanine phosphoribosyltransferase. Eur J Med Chem 2018;159:10-22. [PMID: 30265958 DOI: 10.1016/j.ejmech.2018.09.039] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
17 Heckmann JM, Marais S. Management Issues in Myasthenia Gravis Patients Living With HIV: A Case Series and Literature Review. Front Neurol 2020;11:775. [PMID: 32973647 DOI: 10.3389/fneur.2020.00775] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
18 Goroh MMD, van den Boogaard CHA, Ibrahim MY, Tha NO, Swe, Robinson F, Lukman KA, Jeffree MS, William T, Ralph AP. Factors Affecting Continued Participation in Tuberculosis Contact Investigation in a Low-Income, High-Burden Setting. Trop Med Infect Dis 2020;5:E124. [PMID: 32751073 DOI: 10.3390/tropicalmed5030124] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
19 Santos JC, Silva JB, Rangel MA, Barbosa L, Carvalho I. Preventive therapy compliance in pediatric tuberculosis - A single center experience. Pulmonology 2020;26:78-83. [PMID: 31427215 DOI: 10.1016/j.pulmoe.2019.06.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
20 Scandurra G, Degeling C, Douglas P, Dobler CC, Marais B. Tuberculosis in migrants - screening, surveillance and ethics. Pneumonia (Nathan) 2020;12:9. [PMID: 32923311 DOI: 10.1186/s41479-020-00072-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
21 Wang PH, Lin CH, Chang TH, Wu CS. Chest roentgenography is complementary to interferon-gamma release assay in latent tuberculosis infection screening of rheumatic patients. BMC Pulm Med 2020;20:232. [PMID: 32867745 DOI: 10.1186/s12890-020-01274-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Kweon OJ, Lim YK, Kim HR, Kim TH, Lee MK. Evaluation of Standard E TB-Feron Enzyme-Linked Immunosorbent Assay for Diagnosis of Latent Tuberculosis Infection in Health Care Workers. J Clin Microbiol 2019;57:e01347-19. [PMID: 31533984 DOI: 10.1128/JCM.01347-19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
23 Marais BJ. Preventing tuberculosis in household contacts crucial to protect children and contain epidemic spread. Lancet Glob Health 2018;6:e1260-1. [PMID: 30266569 DOI: 10.1016/S2214-109X(18)30449-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
24 Malik AA, Becerra MC, Lash TL, Cranmer LM, Omer SB, Fuad J, Siddiqui S, Amanullah F, Jaswal M, Salahuddin N, Keshavjee S, Hussain H, Gandhi NR. Risk Factors for Adverse Events in Household Contacts Prescribed Preventive Treatment for Drug-resistant Tuberculosis Exposure. Clin Infect Dis 2021;72:1709-15. [PMID: 32266942 DOI: 10.1093/cid/ciaa327] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Marais BJ. Symptom-based screening of children with household tuberculosis contact. Lancet Respir Med 2018;6:235-7. [PMID: 29273537 DOI: 10.1016/S2213-2600(17)30496-4] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
26 Velen K, Nhung NV, Anh NT, Cuong PD, Hoa NB, Cuong NK, Dung NH, Sy DN, Britton WJ, Marks GB, Fox GJ. Risk factors for TB among household contacts of patients with smear-positive TB in eight provinces of Vietnam: a nested case-control study. Clin Infect Dis 2020:ciaa1742. [PMID: 33215197 DOI: 10.1093/cid/ciaa1742] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Hirsch-Moverman Y, Mantell JE, Lebelo L, Wynn C, Hesseling AC, Howard AA, Nachman S, Frederix K, Maama LB, El-Sadr WM. Tuberculosis preventive treatment preferences among care givers of children in Lesotho: a pilot study. Int J Tuberc Lung Dis 2018;22:858-62. [PMID: 29991393 DOI: 10.5588/ijtld.17.0809] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
28 Hussain H, Malik AA. Investing in drug-resistant tuberculosis household contact management and preventive treatment. The Lancet Global Health 2022. [DOI: 10.1016/s2214-109x(22)00200-5] [Reference Citation Analysis]
29 Paton NI, Borand L, Benedicto J, Kyi MM, Mahmud AM, Norazmi MN, Sharma N, Chuchottaworn C, Huang YW, Kaswandani N, Le Van H, Lui GCY, Mao TE. Diagnosis and management of latent tuberculosis infection in Asia: Review of current status and challenges. Int J Infect Dis 2019;87:21-9. [PMID: 31301458 DOI: 10.1016/j.ijid.2019.07.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
30 Reuter A, Hughes J, Furin J. Challenges and controversies in childhood tuberculosis. The Lancet 2019;394:967-78. [DOI: 10.1016/s0140-6736(19)32045-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 6] [Article Influence: 6.7] [Reference Citation Analysis]
31 Paradkar M, Padmapriyadarsini C, Jain D, Shivakumar SVBY, Thiruvengadam K, Gupte AN, Thomas B, Kinikar A, Sekar K, Bharadwaj R, Dolla CK, Gaikwad S, Elilarasi S, Lokhande R, Reddy D, Murali L, Kulkarni V, Pradhan N, Hanna LE, Pattabiraman S, Kohli R, S R, Suryavanshi N, B M S, Cox SR, Selvaraju S, Gupte N, Mave V, Gupta A, Bollinger RC; CTRIUMPH-RePORT India Study Team. Tuberculosis preventive treatment should be considered for all household contacts of pulmonary tuberculosis patients in India. PLoS One 2020;15:e0236743. [PMID: 32726367 DOI: 10.1371/journal.pone.0236743] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
32 Suryavanshi N, Murrill M, Gupta A, Hughes M, Hesseling A, Kim S, Naini L, Jones L, Smith B, Gupte N, Dawson R, Mave V, Meshram S, Mendoza-Ticona A, Sanchez J, Kumarasamy N, Comins K, Conradie F, Shenje J, Nerette Fontain S, Garcia-Prats A, Asmelash A, Nedsuwan S, Mohapi L, Lalloo U, Cristina Garcia Ferreira A, Okeyo E, Swindells S, Churchyard G, Shah NS. Willingness to Take Multidrug-resistant Tuberculosis (MDR-TB) Preventive Therapy Among Adult and Adolescent Household Contacts of MDR-TB Index Cases: An International Multisite Cross-sectional Study. Clin Infect Dis 2020;70:436-45. [PMID: 30919881 DOI: 10.1093/cid/ciz254] [Reference Citation Analysis]
33 Perumal P, Abdullatif MB, Garlant HN, Honeyborne I, Lipman M, McHugh TD, Southern J, Breen R, Santis G, Ellappan K, Kumar SV, Belgode H, Abubakar I, Sinha S, Vasan SS, Joseph N, Kempsell KE. Validation of Differentially Expressed Immune Biomarkers in Latent and Active Tuberculosis by Real-Time PCR. Front Immunol 2020;11:612564. [PMID: 33841389 DOI: 10.3389/fimmu.2020.612564] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
34 Riccardi N, Alagna R, Motta I, Ferrarese M, Castellotti P, Nicolini LA, Diaw MM, Ndiaye M, Cirillo D, Codecasa L, Besozzi G. Towards ending TB: civil community engagement in a rural area of Senegal: results, challenges and future proposal. Infect Dis (Lond) 2019;51:392-4. [PMID: 30773087 DOI: 10.1080/23744235.2019.1572920] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
35 Marais BJ. Newer Drugs for Tuberculosis Prevention and Treatment in Children. Indian J Pediatr 2019;86:725-31. [PMID: 30707347 DOI: 10.1007/s12098-018-02854-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
36 Goletti D, Petrone L, Ippolito G, Niccoli L, Nannini C, Cantini F. Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs. Expert Rev Anti Infect Ther 2018;16:501-12. [PMID: 29848120 DOI: 10.1080/14787210.2018.1483238] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 6.8] [Reference Citation Analysis]
37 Hall J, Kabir TM, Shih P, Degeling C. Insights into culturally appropriate latent tuberculosis infection (LTBI) screening in NSW: perspectives of Indian and Pakistani migrants. Aust N Z J Public Health 2020;44:353-9. [PMID: 32776658 DOI: 10.1111/1753-6405.13021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
38 Kim BK, Kim HJ, Kim HJ, Cha JH, Lee JB, Jeon J, Kim CY, Kim Y, Kim JH, Shin C, Lee SH. Experiences of Latent Tuberculosis Infection Treatment for the North Korean Refugees. Tuberc Respir Dis (Seoul) 2019;82:306-10. [PMID: 31172709 DOI: 10.4046/trd.2019.0034] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
39 Huang H, Yuan G, Du Y, Cai X, Liu J, Hu C, Liang B, Hu G, Tang X, Zhou Y. Effects of preventive therapy for latent tuberculosis infection and factors associated with treatment abandonment: a cross-sectional study. J Thorac Dis 2018;10:4377-86. [PMID: 30174886 DOI: 10.21037/jtd.2018.06.138] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
40 Kendall EA, Hussain H, Kunkel A, Kubiak RW, Trajman A, Menzies R, Drain PK. Isoniazid or rifampicin preventive therapy with and without screening for subclinical TB: a modeling analysis. BMC Med 2021;19:315. [PMID: 34903214 DOI: 10.1186/s12916-021-02189-w] [Reference Citation Analysis]
41 Wu C, Su H, Chou C, Liu J, Lee C, Dai L, Yang C. An observational study on prevalence of latent tuberculosis infection and outcome of 3HP treatment in patients under hemodialysis in Taiwan. Journal of the Formosan Medical Association 2021;120:1350-60. [DOI: 10.1016/j.jfma.2020.10.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
42 Álvaro-Gracia JM, García-Llorente JF, Valderrama M, Gomez S, Montoro M. Update on the Safety Profile of Tofacitinib in Rheumatoid Arthritis from Clinical Trials to Real-World Studies: A Narrative Review. Rheumatol Ther 2021;8:17-40. [PMID: 33245555 DOI: 10.1007/s40744-020-00258-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
43 Banerjee U, Sankar S, Singh A, Chandra N. A Multi-Pronged Computational Pipeline for Prioritizing Drug Target Strategies for Latent Tuberculosis. Front Chem 2020;8:593497. [PMID: 33381491 DOI: 10.3389/fchem.2020.593497] [Reference Citation Analysis]
44 Fargher J, Reuter A, Furin J. Demanding an end to tuberculosis: treatment of tuberculosis infection among persons living with and without HIV. Curr Opin HIV AIDS 2019;14:21-7. [PMID: 30407203 DOI: 10.1097/COH.0000000000000517] [Reference Citation Analysis]
45 Cantini F, Blandizzi C, Niccoli L, Petrone L, Goletti D. Systematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus Kinases. Expert Opin Drug Saf 2020;19:861-72. [PMID: 32552289 DOI: 10.1080/14740338.2020.1774550] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
46 Otero L, Battaglioli T, Ríos J, De la Torre Z, Trocones N, Ordoñez C, Seas C, Van der Stuyft P. Contact evaluation and isoniazid preventive therapy among close and household contacts of tuberculosis patients in Lima, Peru: an analysis of routine data. Trop Med Int Health 2020;25:346-56. [PMID: 31758837 DOI: 10.1111/tmi.13350] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
47 Navas C, Torres-Duque CA, Munoz-Ceron J, Álvarez C, García JR, Zarco L, Vélez LA, Awad C, Castro CA. Diagnosis and treatment of latent tuberculosis in patients with multiple sclerosis, expert consensus. On behalf of the Colombian Association of Neurology, Committee of Multiple Sclerosis. Mult Scler J Exp Transl Clin 2018;4:2055217317752202. [PMID: 29372069 DOI: 10.1177/2055217317752202] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
48 Min J, Kim HW, Stagg HR, Lipman M, Rangaka MX, Myong JP, Yim HW, Lim JU, Lee Y, Koo HK, Lee SS, Park JS, Cho KS, Kim JS. Latent tuberculosis infection screening and treatment in congregate settings (TB FREE COREA): protocol for a prospective observational study in Korea. BMJ Open 2020;10:e034098. [PMID: 32075836 DOI: 10.1136/bmjopen-2019-034098] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Singh A, Prasad R, Balasubramanian V, Gupta N. Drug-Resistant Tuberculosis and HIV Infection: Current Perspectives. HIV AIDS (Auckl) 2020;12:9-31. [PMID: 32021483 DOI: 10.2147/HIV.S193059] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
50 Andronikou S, Grier D, Minhas K. Reliability of chest radiograph interpretation for pulmonary tuberculosis in the screening of childhood TB contacts and migrant children in the UK. Clin Radiol 2021;76:122-8. [PMID: 33010931 DOI: 10.1016/j.crad.2020.08.035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
51 Martin-Sanchez M, Brugueras S, de Andrés A, Simon P, Gorrindo P, Ros M, Masdeu E, Millet JP, Caylà JA, Orcau À; Contact Tracing Group of the Tuberculosis Investigation Unit of Barcelona. Tuberculosis incidence among infected contacts detected through contact tracing of smear-positive patients. PLoS One 2019;14:e0215322. [PMID: 30986227 DOI: 10.1371/journal.pone.0215322] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
52 Reuter A, Furin J. Treating Drug-resistant Tuberculosis Infection: No More Excuses. Clin Infect Dis 2021;72:1716-8. [PMID: 32266941 DOI: 10.1093/cid/ciaa328] [Reference Citation Analysis]
53 Sakiyama M, Kozaki Y, Komatsu T, Niwa K, Suzuki H, Ota M, Ono Y, Miyagawa Y, Kiyozumi T, Kawana A. Specificity of tuberculin skin test improved by BCG immunization schedule change in Japan. J Infect Chemother 2021;27:1306-10. [PMID: 33952418 DOI: 10.1016/j.jiac.2021.04.016] [Reference Citation Analysis]
54 Sentís A, Vasconcelos P, Machado RS, Caylà JA, Guxens M, Peixoto V, Duarte R, Carvalho I, Carvalho C. Failure to complete treatment for latent tuberculosis infection in Portugal, 2013-2017: geographic-, sociodemographic-, and medical-associated factors. Eur J Clin Microbiol Infect Dis 2020;39:647-56. [PMID: 31797155 DOI: 10.1007/s10096-019-03765-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
55 Howard-Jones AR, Marais BJ. Tuberculosis in children: screening, diagnosis and management. Curr Opin Pediatr 2020;32:395-404. [PMID: 32374579 DOI: 10.1097/MOP.0000000000000897] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
56 Ramos-Espinosa O, Mata-Espinosa D, Francisco-Cruz A, López-Torres MO, Hernández-Bazán S, Barrios-Payán J, Marquina-Castillo B, Carretero M, Del Río M, Hernández-Pando R. Immunotherapeutic effect of adenovirus encoding antimicrobial peptides in experimental pulmonary tuberculosis. J Leukoc Biol 2021. [PMID: 33682193 DOI: 10.1002/JLB.4MA0920-627R] [Reference Citation Analysis]
57 Wong YJ, Noordin NM, Keshavjee S, Lee SWH. Impact of latent tuberculosis infection on health and wellbeing: a systematic review and meta-analysis. Eur Respir Rev 2021;30:200260. [PMID: 33408089 DOI: 10.1183/16000617.0260-2020] [Reference Citation Analysis]
58 Zellweger J; TB Competence Center, Swiss Lung Association, Berne, Switzerland. Latent Tuberculosis Infection. European Respiratory & Pulmonary Diseases 2018;4:21. [DOI: 10.17925/erpd.2018.4.1.21] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
59 Malik AA, Fuad J, Siddiqui S, Amanullah F, Jaswal M, Barry Z, Jabeen F, Fatima R, Yuen CM, Salahuddin N, Khan AJ, Keshavjee S, Becerra MC, Hussain H. Tuberculosis Preventive Therapy for Individuals Exposed to Drug-resistant Tuberculosis: Feasibility and Safety of a Community-based Delivery of Fluoroquinolone-containing Preventive Regimen. Clin Infect Dis 2020;70:1958-65. [PMID: 31190072 DOI: 10.1093/cid/ciz502] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
60 Haley CA. Treatment of Latent Tuberculosis Infection. Microbiol Spectr 2017;5. [PMID: 28409555 DOI: 10.1128/microbiolspec.TNMI7-0039-2016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
61 Slayden RA, Dawson CC, Cummings JE. Toxin-antitoxin systems and regulatory mechanisms in Mycobacterium tuberculosis. Pathog Dis 2018;76. [PMID: 29788125 DOI: 10.1093/femspd/fty039] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 8.5] [Reference Citation Analysis]
62 Girase PS, Dhawan S, Kumar V, Shinde SR, Palkar MB, Karpoormath R. An appraisal of anti-mycobacterial activity with structure-activity relationship of piperazine and its analogues: A review. Eur J Med Chem 2021;210:112967. [PMID: 33190957 DOI: 10.1016/j.ejmech.2020.112967] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
63 Li TL, Chan TH, Wang CH, Jou R, Yu MC, Putri DU, Lee CH, Lin YH. Acquired Resistance to Isoniazid During Isoniazid Monotherapy in a Subject with Latent Infection Following Household Rifampicin-Resistant Tuberculosis Contact: A Case Report. Infect Drug Resist 2021;14:1505-9. [PMID: 33907428 DOI: 10.2147/IDR.S304799] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Onyango DO, Yuen CM, Cain KP, Ngari F, Masini EO, Borgdorff MW. Reduction of HIV-associated excess mortality by antiretroviral treatment among tuberculosis patients in Kenya. PLoS One 2017;12:e0188235. [PMID: 29145454 DOI: 10.1371/journal.pone.0188235] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
65 Parvaresh L, Bag SK, Cho JG, Heron N, Assareh H, Norton S, Corbett S, Marais BJ. Monitoring tuberculosis contact tracing outcomes in Western Sydney, Australia. BMJ Open Respir Res 2018;5:e000341. [PMID: 30397487 DOI: 10.1136/bmjresp-2018-000341] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
66 González Fernández L, Casas EC, Singh S, Churchyard GJ, Brigden G, Gotuzzo E, Vandevelde W, Sahu S, Ahmedov S, Kamarulzaman A, Ponce-de-León A, Grinsztejn B, Swindells S. New opportunities in tuberculosis prevention: implications for people living with HIV. J Int AIDS Soc 2020;23:e25438. [PMID: 31913556 DOI: 10.1002/jia2.25438] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
67 Denholm JT, Silva DS, Burhan E, Chaisson RE. Tuberculosis Elimination in the Asia-Pacific Region and the WHO Ethics Guidance. Trop Med Infect Dis 2018;3:E115. [PMID: 30384409 DOI: 10.3390/tropicalmed3040115] [Reference Citation Analysis]
68 Huaman MA, Sterling TR. Treatment of Latent Tuberculosis Infection-An Update. Clin Chest Med 2019;40:839-48. [PMID: 31731988 DOI: 10.1016/j.ccm.2019.07.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
69 Abubakar I, Chakaya J, Maeurer M, Zumla A. Towards optimal treatment for latent Mycobacterium tuberculosis infection. Lancet Respir Med 2019;7:195-7. [PMID: 30823969 DOI: 10.1016/S2213-2600(19)30036-0] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
70 Qader GQ, Seddiq MK, Rashidi KM, Manzoor L, Hamim A, Akhgar MH, Rahman L, Dryer S, Boyd-Boffa M, Somji A, Melese M, Suarez PG. Prevalence of latent tuberculosis infection among health workers in Afghanistan: A cross-sectional study. PLoS One 2021;16:e0252307. [PMID: 34061873 DOI: 10.1371/journal.pone.0252307] [Reference Citation Analysis]
71 Hannah A, Dick M. Identifying gaps in the quality of latent tuberculosis infection care. J Clin Tuberc Other Mycobact Dis 2020;18:100142. [PMID: 31956699 DOI: 10.1016/j.jctube.2020.100142] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
72 Feng JY, Huang WC, Lin SM, Wang TY, Lee SS, Shu CC, Pan SW, Chen CY, Lin CB, Wei YF, Tung CL, Li CP, Su WJ. Safety and treatment completion of latent tuberculosis infection treatment in the elderly population-A prospective observational study in Taiwan. Int J Infect Dis 2020;96:550-7. [PMID: 32434083 DOI: 10.1016/j.ijid.2020.05.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
73 Reuter A, Seddon JA, Marais BJ, Furin J. Preventing tuberculosis in children: A global health emergency. Paediatr Respir Rev 2020;36:44-51. [PMID: 32253128 DOI: 10.1016/j.prrv.2020.02.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Goletti D, Navarra A, Petruccioli E, Cimaglia C, Compagno M, Cuzzi G, De Carli G, Fondaco L, Franzetti F, Giannetti A, Gori A, Lapadula G, Lichtner M, Mastroianni CM, Mazzotta V, Orchi N, Pavone P, Piacentini D, Pirriatore V, Pontali E, Sarmati L, Spolti A, Tacconelli E, Galli M, Antinori A, Calcagno A, Girardi E. Latent tuberculosis infection screening in persons newly-diagnosed with HIV infection in Italy: A multicentre study promoted by the Italian Society of Infectious and Tropical Diseases. Int J Infect Dis 2020;92:62-8. [PMID: 31887456 DOI: 10.1016/j.ijid.2019.12.031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
75 Sousa J, Saraiva M. Paradigm changing evidence that alter tuberculosis perception and detection: Focus on latency. Infect Genet Evol 2019;72:78-85. [PMID: 30576838 DOI: 10.1016/j.meegid.2018.12.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
76 Padmapriyadarsini C, Das M, Burugina Nagaraja S, Rajendran M, Kirubakaran R, Chadha S, Tharyan P. Is Chemoprophylaxis for Child Contacts of Drug-Resistant TB Patients Beneficial? A Systematic Review. Tuberc Res Treat 2018;2018:3905890. [PMID: 29808119 DOI: 10.1155/2018/3905890] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
77 Aksenova VA, Vasilyeva IA, Kasaeva TC, Samoilova AG, Pshenichnaya NY, Tyulkova TE. Latent tuberculosis infection in children and adolescents in Russia. Int J Infect Dis 2020;92S:S26-30. [PMID: 32114196 DOI: 10.1016/j.ijid.2020.02.038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]